結合型ワクチンの世界市場規模：タイプ別、適応疾患別、病原体別、患者タイプ別、地域別、範囲および予測

結合型ワクチンの市場規模と予測

結合型ワクチンの市場規模は、2024年に167億米ドルと評価され、2026～2032年にCAGR 11%で成長し、2032年には382億7,000万米ドルに達すると予測されます。

• 結合型ワクチンはサブユニットワクチンで、特に細菌表面に存在する弱い抗原に対してより強い免疫反応を引き起こすように設計されています。
• 結合型ワクチンは、免疫学的記憶を誘導し、細菌の無症候性保菌率を低下させることにより、集団免疫を実質的に引き出すことが可能です。
• 結合型ワクチンは肺炎球菌多糖体を用いて開発されており、7価、9価、さらには11価のものが臨床試験中であり、髄膜炎菌A群およびC群を標的とした結合型ワクチンも開発されているが、髄膜炎菌B群が課題となっています。
• 結合型ワクチンには、髄膜炎菌C群結合型（MnCC）、インフルエンザ菌b型（Hib）、肺炎球菌結合型（PnC）の3種類があります。
• 肺炎球菌結合型ワクチンは、肺炎球菌性疾患の原因となる細菌を予防します。肺炎球菌結合型ワクチンには3種類（PCV13、PCV15、PCV20）があります。

世界の結合型ワクチン市場力学

主な市場促進要因

• 乳幼児の早期保護：プライミングの向上は主な利点の1つです。従来の予防接種とは異なり、結合型ワクチンは、免疫系が発達途上にある新生児や幼児の免疫応答（i.e.抗体応答、特にIgG1抗体）をうまく引き出すことができます。これにより、重要な発育段階において、より早期の疾病予防が可能となります。
• 長期にわたる免疫とブースター効果：結合体を含むワクチンは、免疫系の記憶を呼び起こすのに優れています。寿命の長いメモリーB細胞の増殖を促します。同じ細菌に再び遭遇した場合、たとえ数年後であっても、これらの記憶細胞は特定の抗原を思い出すことができるため、すぐに強力な免疫反応を起こすことができます。再接種を受ける場合、これは免疫力をさらに強化するブースター効果となります。
• 粘膜保護：結合型ワクチンは、従来のワクチンの主な標的である血流抗体産生に加えて、分泌型IgAおよび粘膜活性型IgG抗体合成を誘導することができます。粘膜表面は多くの病気に対する身体の第一防御ラインであり、これらの特殊な抗体はその防御に不可欠です。
• より優れた効果と正確な標的：結合型ワクチン接種は「親和性成熟」プロセスを促進します。これは、免疫系が抗体産生を徐々に向上させた結果、標的抗原に対する抗体の親和性が高くなる（結合が強固になる）ことを意味します。抗体が細菌を免疫細胞によって駆除するための目印となるオプソニン化機能が、より緊密に結合することによって向上し、ワクチンの有効性が高まるのです。
• Hibおよび肺炎球菌性髄膜炎の大幅な減少：PCVとHib（インフルエンザ菌b型）に対する現在の予防接種は、小児髄膜炎の回避に非常に成功しています。結合型ワクチン接種は、細菌を保有していても症状を示さない人の数を減少させることにより、集団免疫を促進する上で大きな役割を果たしています。このことは、ワクチン接種を受けていない人であっても、保菌者が少ないということは集団内での感染リスクが低いということであり、保護されていることを意味します。
• 急性中耳炎と市中肺炎の発生率の上昇：これらのワクチンは、髄膜炎や敗血症のような危険で侵襲的な病気を防ぐだけでなく、広範囲に及ぶ効果があります。これらのワクチンは、一般的な良性疾患の治療にも非常に有効です。結合型ワクチンの接種により、成人および小児の急性中耳炎（耳の感染症）や市中肺炎の発生率が大幅に低下します。これらの結果は、将来的に予防戦略を最適化することで、より健康的な地域社会を実現できる可能性を示しています。米国では毎年15万人が肺炎球菌性肺炎で入院し、死亡率は5～7％です。

主な課題

• コストと手頃な価格：通常のワクチンに比べ、結合型ワクチンは研究・製造コストが高くつくことが多いです。このような費用の増加は、1回あたりの接種価格の上昇につながり、新興国での利用を制限する可能性があります。さらに、結合型ワクチンのような最近の高価なワクチンの費用は、高価で未発達であるため政府資金で賄うことができず、新興諸国はワクチンの研究・購入費用を捻出することができないです。
• 限られたインフラとコールドチェーンの課題：サプライチェーン全体で適切な保管温度を確保するため、結合型ワクチンの効果的な供給には強力なコールドチェーン・インフラが必要です。南アフリカや中東、アジアのような資源やインフラが不十分な地域では、これが深刻な問題となり、ワクチンの劣化や有効性の低下を招く可能性があります。例えば、インドでは1～59カ月の小児が肺炎に罹患した場合の死亡率は12％、乳幼児が罹患した場合の死亡率は3％です。
• 一般市民の認識とワクチンへの抵抗感：結合型ワクチンの普及は、誤った情報や予防接種に対する懐疑心によって妨げられている可能性があります。ワクチン接種のためらいと闘い、可能な限り高い接種率を保証するためには、教育・啓蒙キャンペーンを通じて一般の人々の懸念に対処することが不可欠です。
• 細菌の血清型と株の変化：肺炎球菌のような一部の細菌は、異なる血清型や株を持っています。結合型ワクチン接種は特定の血清型を標的としているが、ワクチンでは防御できない新興の菌株や新種の菌株は依然として危険です。この問題を先取りするためには、研究者は新型血清型を標的とするワクチンや、より幅広い効果を持つワクチンを開発し続けなければならないです。例えば、侵襲性肺炎球菌性疾患の約75％、肺炎球菌性髄膜炎の83％は小児に発症します。

主要動向：

• 小児予防接種プログラムの改善に対する需要の高まり：市場の需要は、結合型ワクチン接種の利点、特に幼い乳幼児を致命的な感染症から守る能力に関する知識の高まりによって牽引されています。低開発国における小児期の予防接種制度の改善に対する関心の高まりは、市場成長の新たな道を開くものです。例えばインドでは、2020年まで約90%の子どもたちが救命ワクチンを利用できます。
• ワクチン目標の増加：研究開発の目標は、より多様な感染症に対応できる結合型ワクチンを開発することです。これには、さまざまな髄膜炎菌株や新規肺炎球菌血清型によって引き起こされる髄膜炎などの病気を予防するための予防接種の継続的な創出が含まれます。
• 技術開発：ワクチン製造方法の改善により、より効果的でリーズナブルな価格の結合型ワクチンが作られつつあります。これにより、特に資源が限られている環境において、入手しやすく、手頃な価格で接種できるようになる可能性があります。遺伝子編集のような新技術の助けを借りて、免疫原性を高めたり、より広い予防効果を持つ新しい結合型ワクチンが開発される可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 結合型ワクチン市場：タイプ別

• 一価結合型ワクチン
• 多価結合型ワクチン

第5章 結合型ワクチン市場：適応疾患別

• 肺炎球菌
• インフルエンザ
• DTPワクチン
• 髄膜炎菌
• 腸チフス

第6章 結合型ワクチン市場：病原体タイプ別

• 細菌性結合型ワクチン
• ウイルス性結合型ワクチン
• 混合（ウイルスと細菌）結合型ワクチン

第7章 結合型ワクチン市場：患者タイプ別

• 小児
• 成人

第8章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第9章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第10章 競合情勢

• 主要企業
• 市場シェア分析

第11章 企業プロファイル

• Bharat Biotech
• Biological E
• CSL Limited
• Glaxo SmithKline, plc.
• Merck and Company
• Bio-Rad
• Novartis AG
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India

第12章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第13章 付録

• 略語リスト
• 出典と参考文献

Conjugate Vaccine Market Size And Forecast

Conjugate Vaccine Market size was valued at USD 16.7 Billion in 2024 and is projected to reach USD 38.27 Billion by 2032, growing at a CAGR of 11% from 2026-2032.

• A conjugate vaccine is a subunit vaccine that is designed to elicit a stronger immune response against weak antigens, especially those found on the surface of bacteria.
• The conjugate vaccine is capable of substantially eliciting herd immunity by inducing immunological memory and lowering the bacteria's asymptomatic carriage.
• Conjugate vaccines are being developed using pneumococcal polysaccharides, with 7, 9, and even 11-valent versions undergoing clinical trials, and conjugate vaccines targeting meningococcal groups A and C, but the group B meningococcal presents a challenge.
• Conjugate vaccines are available in three types Meningococcal Group C Conjugate (MnCC), Hemophilus Influenzae Type b (Hib), and Pneumococcal Conjugate (PnC).
• Pneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. There are three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20).

Global Conjugate Vaccine Market Dynamics

The key market dynamics that are shaping the global Conjugate Vaccine Market include:

Key Market Drivers

• Early Protection for Infants: Improved priming is one of the main benefits. Contrary to some conventional vaccinations, conjugate vaccines can successfully elicit an immune response in newborns and young children whose immune systems are still developing (i.e., an antibody response, specifically IgG1 antibodies). This enables earlier illness prevention throughout crucial developmental phases.
• Long-Term Immunity & Booster Effect: Vaccines containing conjugates are excellent at igniting the memory of the immune system. They encourage the growth of memory B cells with a long lifespan. When the same germs are encountered again, even years later, these memory cells can quickly mount a potent immune response because they can recall the particular antigen. When obtaining a revaccination, this translates to a booster effect that strengthens immunity even more.
• Mucosal Protection: Conjugate vaccines can induce secretory IgA and mucosally active IgG antibody synthesis, in addition to the bloodstream antibody production that is the main target of traditional vaccines. Mucosal surfaces are the body's first line of defense against numerous illnesses, and these particular antibodies are essential for their protection.
• Better Effectiveness and Precise Targeting: Conjugate vaccinations encourage the "affinity maturation" process. This indicates that as a result of the immune system's gradual improvement in antibody production, the resulting antibodies have a higher affinity (tighter binding) to the target antigen. The opsonizing function, in which antibodies mark bacteria for eradication by immune cells, is improved by this closer match, thus increasing the vaccine's efficacy.
• Significant Reduction in Hib and Pneumococcal Meningitis: The current vaccinations against PCV and Hib (Haemophilus Influenzae type b) are exceptionally successful in avoiding childhood meningitis. Conjugate vaccinations play a major role in promoting herd immunity by lowering the number of people who carry bacteria but do not exhibit any symptoms. This implies that even individuals who have not received vaccinations are protected since fewer carriers equate to a lower risk of transmission within the population.
• Rising Incidence of Acute Otitis Media and Community-Acquired Pneumonia: These vaccines have far-reaching effects that go well beyond shielding against dangerous, invasive illnesses like meningitis and sepsis. They are incredibly successful in treating common benign ailments. Conjugate vaccinations considerably lower the incidence of acute otitis media (ear infections) and community-acquired pneumonia in both adults and children. These results pave the way for promising future prevention strategy optimizations that could result in even healthier communities. In the United States every year 150,000 people are hospitalized for Pneumococcal pneumonia and the mortality rate is 5%-7%.

Key Challenges:

• Cost and Affordability: Compared to regular vaccines, conjugate vaccines are frequently more expensive to research and produce. This increased expense may result in a higher price per dosage, which can restrict accessibility in emerging countries. In addition, the expense of more recent and costly vaccines, such as conjugate vaccines, are not covered by government funding as the vaccines are expensive and underdeveloped, and developing countries cannot afford the cost of vaccine research and purchase.
• Limited Infrastructure and Cold Chain Challenges: To ensure appropriate storage temperatures across the supply chain, effective conjugate vaccine delivery necessitates a strong cold chain infrastructure. In areas with inadequate resources or infrastructure, such the regions like South Africa, and Middle East, and Asia this can pose a serious problem and result in vaccine deterioration and decreased efficacy, which is expected to hamper the growth of the Conjugate Vaccine Market in the underdeveloped and developing regions. For instance, the mortality rate in developing regions is increasing, such as in India children with age 1-59 months affected by pneumonia have a 12% mortality rate, and infants affected have a 3% mortality rate.
• Public Perception and Vaccine Hesitancy: The widespread use of conjugate vaccines may be hampered by misinformation and skepticism about vaccinations. To combat vaccine hesitancy and guarantee the highest possible immunization rates, it is imperative to address public concerns through campaigns of education and awareness.
• Changing Bacterial Serotypes and Strains: Some bacteria, such as pneumococcus, have different serotypes and strains. Conjugate vaccinations target particular serotypes, but emerging or novel strains that are not protected by the vaccine can still be dangerous. To remain ahead of this problem, researchers must continue to create vaccinations that target novel serotypes or vaccines with a wider spectrum of effects. For instance, about 75% of invasive pneumococcal disease and 83% of pneumococcal meningitis occur in children.

Key Trends:

• Growing Demand for Better Childhood Immunization Programs:Demand in the market is being driven by rising knowledge of the advantages of conjugate vaccinations, particularly their capacity to protect young infants against deadly infections. Growing attention to improving childhood immunization systems in underdeveloped nations opens up new avenues for market growth. For instance, in India around 90% of children have access to life-saving vaccines till 2020.
• Increased Vaccine Targets: The goal of research and development is to create conjugate vaccines that can combat a larger variety of infections. This involves the continuous creation of vaccinations to prevent illnesses like meningitis brought on by different meningococcal strains and novel pneumococcal serotypes.
• Technological Developments: More effective and reasonably priced conjugate vaccines are being created as a result of improvements in vaccine production methods. This could increase accessibility and affordability, especially in environments with limited resources. Novel combination vaccines with enhanced immunogenicity or wider protection could be developed with the help of emerging technologies like gene editing.

Global Conjugate Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Conjugate Vaccine Market:

North America

• North America is known for its fast-paced atmosphere, which facilitates the rapid adoption of vaccination breakthroughs. This flexibility makes it possible to increase the development of vaccines and investigate novel solutions with more ease. This is in contrast to certain regions of Europe and Asia where adoption rates may be lower.
• Public healthcare systems that are well-developed and provide extensive coverage for medical services are found throughout North America. Strong assistance is extended to vaccine research and development (R&D) endeavors. This encourages creativity and concentrates attention on enhancing public health via immunization campaigns. For instance, in the U.S. in 2022 around 9% of children ages 6 months to 17 years have been vaccinated by influenza vaccination during the past 12 months.
• An established healthcare system and the existence of large pharmaceutical companies offer a solid basis for the conjugate vaccination industry in North America. The region's supremacy in this sector is mostly due to these factors. For instance, in 2021, the United States spent around 17.8 & of the gross domestic product on healthcare.
• The increasing prevalence of influenza in the U.S. is propelling the growth of the Conjugate Vaccine Market. For instance, in 2023 around 121 children died due to influenza. According to the Centers for Disease Control and Prevention, at least 30 Million people are affected 340,00 are hospitalized, and 21,000 deaths due to the flu.

Asia-Pacific

• Asia-Pacific is the fastest-growing region in the Conjugate Vaccine Market during the forecast period due to the increasing population and government initiatives for healthcare infrastructure.
• In Asia-Pacific, the population is expanding quickly in many of the member states. This generates a great deal of demand, especially for youngsters, for greater vaccination coverage. Given their efficacy in defending young infants, conjugate vaccinations are ideally positioned to meet this requirement.
• For instance, in India in 2022-23 cases reported of pneumonia in the states are Maharashtra (14078), Assam (11011), Jammu and Kashmir (4952), Madhya Pradesh (39948), Punjab (14965) etc.
• Increasing the prevalence of conjugate vaccines the government is actively taking initiatives such as funding immunization campaigns and investment in research and development. For instance, in India from 2015 to 2020 the immunization coverage in children from the age of 12-23 months is estimated to be 62% in 2015-2016 to 76% in 2019-2020.

Global Conjugate Vaccine Market: Segmentation Analysis

The Global Conjugate Vaccine Market is segmented on the basis of Type, Disease Indication, Pathogen Type, Patient Type, and Geography.

Conjugate Vaccine Market, By Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

Based on Type, the market is segmented into Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine. The Multivalent Conjugate Vaccines segment is substantially leading in the Conjugate Vaccine Market and is expected to continue its growth during the forecast period. A significant breakthrough in the battle against infectious illnesses has been made with the development of multivalent conjugate vaccines. Their capacity to offer more comprehensive protection, economy, and effectiveness is propelling market expansion and clearing the path for a healthier future. Technological developments along with encouraging policy measures from the government will probably ensure that multivalent conjugate vaccines continue to dominate the conjugate vaccine industry.

Conjugate Vaccine Market, By Disease Indication

• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Typhoid

Based on Disease Indication, the market is segmented into Pneumococcal, Influenza, DTP, Meningococcal, and Typhoid. The increasing prevalence of DTP in children globally is fueling the growth of DTP vaccines all over the world. For instance, in 2022, around 86% and in 2021 around 89% the coverage of DTPcv1 has increased globally and similarly the coverage of DTPcv3 has increased from 81% in 2021 and 84% in 2022. To ensure that children everywhere have a healthier future, ongoing initiatives to increase vaccination rates, broaden immunization programs, and discover novel vaccines are essential. DTP vaccine segments in the Conjugate Vaccine Market emphasize how important these vaccinations are in shielding kids from potentially fatal diseases.

Conjugate Vaccine Market, By Pathogen Type

• Bacterial Conjugate Vaccine
• Viral Conjugate Vaccine
• Combination (Viral And Bacterial) Conjugate Vaccine

Based on Pathogen Type, the market is segmented into Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, and Combination (Viral And Bacterial) Conjugate Vaccine. Bacterial Conjugate Vaccine is significantly leading the Conjugate Vaccine Market. These vaccinations target bacteria specifically, which is a single-celled organism that can cause a variety of diseases. Bacterial conjugate vaccines directly target the bacteria, in contrast to toxoid vaccinations, which concentrate on inactivated bacterial toxins.

Conjugate Vaccine Market, By Patient Type

• Pediatric
• Adults

Based on Patient Type, the market is segmented into Pediatric and Adults. Pediatric segment is substantially leading in the Conjugate Vaccine Market. Hib meningitis is a severe infection that can be fatal for young children. The Hib conjugate vaccine has significantly reduced the burden of this disease. In children, pneumococcal bacteria are the primary cause of sepsis, meningitis, and pneumonia. PCV vaccinations provide essential defense against several infections.

Key Players

The "Global Conjugate Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bharat Biotech, Biological E, CSL Limited, Glaxo SmithKline, plc., Merck and Company, Bio-Rad, Novartis AG, Pfizer Inc., Sanofi Pasteur, and Serum Institute of India. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Conjugate Vaccine Market Recent Developments
• In August 2022, Nigeria announced a vaccine of Bharat Biotech for the immunization of children. Reducing the infectious disease burden amongst children in the developing world, and ensuring nations like Nigeria in the African continent, have access to cost-effective world-class interventions for infants and vulnerable populations. ROTAVAC(R) is safe and effective at preventing diarrheal disease caused by the Rotavirus."
• In July 2023, the Serum Institute of India announced the first conjugate vaccine that protects from the predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive(R) is a vaccine that protects against meningococcal serogroups A, C, W, Y, and X. It was developed over 13 years of collaboration between Serum Institute of India Pvt. Ltd. and PATH, with significant funding from the Foreign, Commonwealth and Development Office of the UK government.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Conjugate Vaccine Market, By Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

5. Conjugate Vaccine Market, By Disease Indication

• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Typhoid

6.Conjugate Vaccine Market, By Pathogen Type

• Bacterial Conjugate Vaccine
• Viral Conjugate Vaccine
• Combination (Viral And Bacterial) Conjugate Vaccine

7.Conjugate Vaccine Market, By Patient Type

• Pediatric
• Adults

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Bharat Biotech
• Biological E
• CSL Limited
• Glaxo SmithKline, plc.
• Merck and Company
• Bio-Rad
• Novartis AG
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References